Omeros Corporation (OMER) Dividend History

Omeros Corporation is an American biopharmaceutical company focused on the discovery, development, and commercialization of drugs for areas such as inflammation, respiratory illness, and Central Nervous System disorders. It leverages its proprietary small-molecule and biologic platforms to develop therapies aimed at underserved medical needs.

201 Elliott Avenue West, Seattle, WA, 98119
Phone: 206-676-5000
Website:

Dividend History

Omeros Corporation currently does not pay dividends

Company News

  • The CNN Money Fear and Greed index showed a slight decline in overall market sentiment, but it remained in the "Greed" zone on Thursday. U.S. stocks closed mixed on Thursday, while the S&P 500 surged to a new all-time high and also recorded its best first-quarter performance in five years. For the quarter, the S&P 500 gained 10.2% to record its best first-quarter gain since 2019. The Dow Jones added 5.6% during the quarter, notching its best first-quarter performance since 2021. On the month, the S&P 500 gained 3.1%, while the Dow added 2.1%. Shares of MSC Industrial Direct Co., Inc. (NYSE: MSM) fell around 2.5% during Thursday’s session after the company reported mixed second-quarter results. Walgreens Boots Alliance Inc (NASDAQ:

    Benzinga
    Featured Companies: MSM NGS PVH WBA
  • U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. Shares of Tesla, Inc. (NASDAQ: TSLA) fell during Monday’s session after the company reportedly saw a decline in February China sales. Tesla sold 60,365 electric vehicles made in China in February, according to preliminary data released by the China Passenger Car Association, as reported by CnEVPost. The breakdown between exports and domestic sales will be available when the detailed report is released in a week. Tesla shares fell 5.4% to $191.79 on Monday. Here are some other big stocks recording losses in today’s session. MMTec, Inc. (NASDAQ: MTC) shares fell 21.8% to $2.00. Avidity Biosciences, Inc. (NASDAQ: RNA) declined 16.6% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy Type 1 patients across multiple endpoints. Playtika Holding Corp. (NASDAQ: PLTK) tumbled 14.8% to $6.44 New York Community Bancorp, Inc. (NASDAQ: NYCB) declined 13.6% to $3.0650 after ...

    Benzinga
  • A look at drugs for drug addiction and the biotech space.

    Zacks Investment Research
    Featured Companies: CYBN
  • As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) On Dec. 4, EyePoint Pharmaceuticals announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E. The company’s stock jumped around 198% over the past five days and has a 52-week high of $22.44 . RSI ...

    Benzinga
    Featured Companies: ALT EYPT OCUL TERN
  • The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Omeros The Trade: Omeros Corporation (NASDAQ: OMER) Director MD Peter Demopulos acquired a total of 10,000 shares an average price of $1.53. To acquire these shares, it cost around $15,300. What’s Happening: Omeros posted a wider loss for the third quarter. What Omeros Does: Omeros Corp is a United States-based ...

    Benzinga
    Featured Companies: ATAI GCI TSHA
Dividend data last updated 06/07/2025 05:22:57 UTC